Related references
Note: Only part of the references are listed.Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma
Donna E. Hansel et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
Guiqin Hou et al.
CANCER LETTERS (2010)
Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
Ker Yu et al.
CANCER RESEARCH (2010)
Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome
David Lindgren et al.
CANCER RESEARCH (2010)
The Phosphoinositide 3-Kinase Regulatory Subunit p85α Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling
Cullen M. Taniguchi et al.
CANCER RESEARCH (2010)
Germline APC mutation spectrum derived from 863 genomic variations identified through a 15-year medical genetics service to French patients with FAP
Arnaud Lagarde et al.
JOURNAL OF MEDICAL GENETICS (2010)
A method and server for predicting damaging missense mutations
Ivan A. Adzhubei et al.
NATURE METHODS (2010)
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K
J. M. Askham et al.
ONCOGENE (2010)
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
Lucie C. Kompier et al.
PLOS ONE (2010)
PTEN and the PI3-Kinase Pathway in Cancer
Nader Chalhoub et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
The role of mTOR in bladder cancer
Kilian M. Gust et al.
CANCER BIOLOGY & THERAPY (2009)
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Bijay S. Jaiswal et al.
CANCER CELL (2009)
Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer
Catherine M. Seager et al.
CANCER PREVENTION RESEARCH (2009)
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Fiona M. Platt et al.
CLINICAL CANCER RESEARCH (2009)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
Inactivation of p53 and Pten promotes invasive bladder cancer
Anna M. Puzio-Kuter et al.
GENES & DEVELOPMENT (2009)
Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication
Efstathios Kastritis et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Activation of RAS Family Genes in Urothelial Carcinoma
I. Boulalas et al.
JOURNAL OF UROLOGY (2009)
A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression
Carolyn L. Buller et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2008)
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity
Elena V. Svirshchevskaya et al.
BMC CANCER (2008)
Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors
Markus Heidenblad et al.
BMC MEDICAL GENOMICS (2008)
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Germline gain-of-function mutations in RAF1 cause Noonan syndrome
M. Abdur Razzaque et al.
NATURE GENETICS (2007)
NRAS and BRAF mutations in melanoma turnours in re ation to clinical characteristics:: a study based on mutation screening by pyrosequencing
Esther Edlundh-Rose et al.
MELANOMA RESEARCH (2006)
TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth
Ken Inoki et al.
CELL (2006)
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors
Elena Lopez-knowles et al.
CANCER RESEARCH (2006)
Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas
Silvia Hernandez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
AH Jebar et al.
ONCOGENE (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma
BSW van Rhijn et al.
CANCER RESEARCH (2004)
Proteins interacting with the tuberous sclerosis gene products
M Rosner et al.
AMINO ACIDS (2004)
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome
BWG van Rhijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The tuberin-hamartin complex negatively regulates β-catenin signaling activity
BC Mak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
β-catenin mutations correlate with over expression of c-myc and cyclin D1 genes in bladder cancer
H Shiina et al.
JOURNAL OF UROLOGY (2002)
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo et al.
ONCOGENE (2000)
Aberrant expression of β-catenin and mutation of exon 3 of the β-catenin gene in renal and urothelial carcinomas
XD Zhu et al.
PATHOLOGY INTERNATIONAL (2000)
H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers
B Przybojewska et al.
CANCER GENETICS AND CYTOGENETICS (2000)
Share Paper
